Advances in the pharmacotherapy of Alzheimer's disease

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 5, 2002, Pages 616-623

  Gauthier, Serge ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; ACETYLCHOLINE; ALPHA TOCOPHEROL; AMYLOID; CALCIUM CHANNEL BLOCKING AGENT; CHOLINE; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; ENZYME INHIBITOR; GALANTAMINE; GAMMA SECRETASE; NEUROTROPIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; VACCINE;

ALZHEIMER DISEASE; CHOLINERGIC TRANSMISSION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DEMENTIA; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MUSCLE CRAMP; NAUSEA; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PATHOGENESIS; PATIENT CARE; PSYCHIATRIC DIAGNOSIS; RATING SCALE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; VERTIGO; VOMITING;

EID: 0036202343     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. The global deterioration scale for assessment of primary degenerative dementia
2. Mini mental state: A practical method for grading the cognitive state of patients for the clinician
3. Neocortical cholinergic neurons in elderly people
4. Neurochemical deficits in pathological brain aging: Specificity and possible relevance for treatment strategies
5. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
6. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
7. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: Possible role in cell loss
8. Age-related loss of calbindin from human basal forebrain cholinergic neurons
9. Partial reversal of anticholinergic amnesia by choline chloride
10. A family intervention to delay nursing home placement of patients with Alzheimer's disease. A randomized controlled trial
11. Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success?
12. Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy
13. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
14. Donepezil improves cognition and global function in Alzheimer disease
15. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
16. Donepezil in the treatment of Alzheimer's disease: Results from a multinational clinical trial
17. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
18. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
19. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
20. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
21. Donepezil: A meta-analysis of individual patient's data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease
22. The disability assessment for dementia scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease
23. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
24. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled study
25. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: Epidemiology and management
26. Galantamine in A.D.: A 6-month randomized, placebo-controlled trial with a 6-month extension
27. A 5-month, randomized, placebo-controlled trial of galantamine in AD
28. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial
29. Recommendations for the management of behavioral and psychological symptoms of dementia
30. Efficacy of galantamine in patients not responding to donepezil (18-week interim results)
31. Galantamine improves sleep in patients withdrawn from donepezil (prelminary results)
32. Therapeutic continuity in Alzheimer's disease: Switching patients to galantamine. Panel discussion: Recommendations for prescribers
33. Alzheimer's disease: Current and future therapeutic perspectives
34. Mild cognitive impairment: Clinical characterization and outcome
35. The recognition, assessment and management of dementing disorders: Conclusions from the Canadian Consensus Conference on Dementia